Confronting a Pandemic

A four-part digital event series with Harvard Medical School Executive Education and STAT News

The COVID-19 crisis is galvanizing rapid change in the health care industry, especially in provider organizations, tech and biopharma. New collaborations, regulatory and reimbursement changes, and novel applications of tech and biopharmaceutical platforms have created new strategies and opportunities.

What does this new way of doing business in health care mean for the COVID-19 pandemic and plans to re-open society? What aspects of our crisis footing will persist and shape our ‘new normal’ in health care?

New Biopharma Models for COVID-19

**View the Recording of New Biopharma Models for COVID-19 »**

Many biotech and pharmaceutical companies have rapidly brought teams, platforms and assets to bear on the COVID-19 crisis. In addition, “rival” companies are forging new open-science-inspired collaborations to discover SARS-CoV-2 therapeutics. Join us as two dynamic R&D leaders discuss how their companies are confronting today’s challenges in unexpected ways.

Moderators:

Rebecca Robbins, Former San Francisco Correspondent, STAT News
Stanley Shaw, Associate Dean, Harvard Medical School Executive Education

Jay Bradner, MD

President, Novartis Institutes for BioMedical Research (NIBR)

Executive Committee Member, Novartis

Andrew Plump, MD, PhD

President, Research & Development, Takeda Pharmaceuticals

Telemedicine- The New Normal?

View the Recording of Telemedicine- The New Normal? »

Health systems have transformed how they use telehealth in the COVID-19 era, moving from small pilots to widespread adoption in just weeks. This has been catalyzed by rapid changes in reimbursement, licensure and clinical workflows. We will explore the lessons to be learned from this transformation and what the future landscape of telehealth will look like. Our panelists will share their perspectives from academic health centers and industry, and from front-line providers to health system leaders to national policymakers.

Moderators:

Erin Brodwin, Health Tech Correspondent, San Francisco, STAT News
Stanley Shaw, Associate Dean, Harvard Medical School Executive Education

John Glaser, PhD

Executive-in-Residence, Harvard Medical School Executive Education

Email John Glaser

Lee Schwamm, MD

VP of Virtual Care, Partners Healthcare Digital Health

Director, MGH Center for Telehealth

Executive Vice Chairman, Department of Neurology, Massachusetts General Hospital

Technology for Surveillance and Contact Tracing

View the Recording of Technology for Surveillance and Contact Tracing »

As businesses plan to re-open amidst COVID-19, there is growing interest in digital tools to help with disease surveillance, contact tracing and enforcing social distancing. Employers, public health departments and large tech companies are all joining the effort. But critical questions remain: Will the tech work? How much privacy are we willing to give up? Do we have enough transparency to allow individuals to make informed decisions? Together with STAT News, this webinar will explore these issues and answer your questions.

Moderators:

Casey Ross, National Technology Correspondent, STAT News
Stanley Shaw, Associate Dean, Harvard Medical School Executive Education

John Brownstein, PhD

Chief Innovation Officer, Boston Children’s Hospital

Professor of Pediatrics, Harvard Medical School

Dena Mendelsohn, JD, MPH

Director, Health Policy and Data Governance at Elektra Labs

The Foundations of Reopening

View the Recording of The Foundations of Reopening »

The COVID-19 conversation is turning towards how we can best re-open society. Two of the pillars of our future new normal are a vaccine, and an effective testing/contact tracing program. In this webinar, we’ll discuss the latest updates on vaccine clinical trials (including Moderna’s phase I report) and the ambitious contact tracing partnership between Partners in Health and the state of Massachusetts. Besides intrinsic technical or logistical challenges, both of these potential solutions also raise tough questions about how effectively and fairly they can be rolled out given our frayed system of health care delivery. Join us as we explore technologic progress but also take a holistic view of how new solutions might work within the reality of our public health infrastructure.

Moderators: